Opinion

Video

Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Author(s):

Elizabeth R. Plimack, MD, MS, FASCO,Neeraj Agarwal, MD

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Related Videos
Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University
4 experts are featured in this series.
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Related Content
Bradley McGregor, MD
January 15th 2025

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Yousef Zakharia, MD
January 14th 2025

Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

lertsakwiman – stock.adobe.com
January 8th 2025

China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

Toni Choueiri, MD
January 8th 2025

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC